Over a month ago
Hot Stocks
According to a post on…
According to a post on the FDA's website, Xenon Pharmaceuticals' treatment of childhood Absence Epilepsy, flunarizine, was granted FDA orphan designation. Reference Link
Show Hide Related Items >> <<
XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham XENE Xenon Pharmaceuticals 05/11/21 Xenon Pharmaceuticals reports Q1 EPS (42c) vs. (22c) last year
Earnings
Reports Q1 revenue…
Reports Q1 revenue $4.36M, consensus $5.15M. Simon Pimstone, Xenon's CEO, said, "We continue to make excellent progress across both our proprietary and partnered programs. In particular, I am pleased to report that we have completed patient screening in our Phase 2b 'X-TOLE' clinical trial evaluating XEN1101 as an adjunctive treatment of focal epilepsy. With the final patients currently in baseline, we anticipate randomization to be completed in June and the release of topline data by the end of the third quarter. Additionally, we continue to initiate new sites to support ongoing patient enrollment in our Phase 3 "EPIK" study, which is evaluating XEN496 as a treatment of KCNQ2 developmental and epileptic encephalopathy."
Show Hide Related Items >> <<
XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham
Conference/Events
Stifel Virtual CNS Day…
Stifel Virtual CNS Day 2021 will be held on March 31-April 1.
Show Hide Related Items >> <<
01/11/21 Zogenix announces 2021 corporate objectives 01/11/21 Zogenix sees Q4 FINTEPLA revenue $8.1M 12/21/20 Zogenix announces EC approval of FINTEPLA oral solution 12/03/20 Zogenix and Tevard Biosciences to develop therapies for Dravet syndrome XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO TSHA Taysha Gene Therapies 03/09/21 Taysha Gene Therapies announces collaboration to advance AAV gene therapies 02/09/21 Taysha Gene Therapies announces multi-year collaborations for AAV gene therapies 01/26/21 Taysha Gene Therapies appoints Timothy Douros as CLO, Tracy Porter as CPO 01/19/21 Taysha gets both rare pediatric disease and orphan drug designations for TSHA-10 03/30/21 Stoke Therapeutics gets MHRA authorization to start clinical trial of STK-001 11/25/20 Stoke Therapeutics announces abstracts for Dravet syndrome at AES 2020 10/07/20 Stoke Therapeutics to move forward with dosing of STK-001 in MONARCH study 03/17/21 Sage Therapeutics' zuranolone for depression shows positive Phase 3 results 03/16/21 Sage Therapeutics announces departure of COO Mike Cloonan 01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 03/29/21 uniQure announces findings from case of HCC in Hemophilia B gene therapy program 03/01/21 uniQure expects cash to fund operations into 2H22 02/08/21 uniQure says DSMB recommends proceeding with Phase I/II trial of AMT-130 12/21/20 uniQure says hemophilia B gene therapy program placed on clinical hold PRAX Praxis Precision Medicines 03/17/21 Praxis Precision Medicines expects cash to fund operations into 4Q22 02/16/21 Praxis Precision Medicines partners with Ciitizen 01/07/21 Praxis receives rare pediatric disease, orphan drug designations for PRAX-222 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 03/22/21 Passage Bio appoints Eliseo Salinas as chief R&D officer 03/08/21 Passage Bio to start PBFT02 clinical program in 1H21 03/08/21 Passage Bio to start Phase 1/2 trial of PBKR03 in 1H21 03/08/21 Passage Bio to dose first patient in global Imagine-1 study in Q1 02/25/21 Karuna announces data from KarXT study in Schizophrenia published 02/25/21 Karuna Therapeutics sees cash, cash equivalents, sufficient into 2023 02/24/21 Karuna Therapeutics' KarXT in schizophrenia meets Phase 2 efficacy endpoint 10/14/20 Karuna says no incidences of syncope reported in KarXT trial CERE Cerevel Therapeutics 01/28/21 Cerevel Therapeutics hosts R&D event to review darigabat 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/19/21 Inspire appoints Bryan Phillips as chief compliance officer, general counsel 01/19/21 Frequency Therapeutics appoints Quentin McCubbin as chief manufacturing officer 03/25/21 Biogen up 3% after tweet claims Tecfidera patents to be granted 03/21/21 Fly Intel: Top five weekend stock stories 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO AVDL Avadel Pharmaceuticals 03/04/21 Avadel, AASM Foundation partner with Young Investigators Research Forum 03/02/21 Avadel Pharmaceuticals announces publication on FT218 studies 03/01/21 Avadel Pharmaceuticals announces FDA acceptance of FT218 NDA 02/17/21 Avadel Pharmaceuticals appoints Richard Kim as CCO 02/26/21 Mizuho Sage Therapeutics downgraded to Neutral from Buy at Mizuho 02/25/21 Oppenheimer Sage Therapeutics price target raised to $102 from $90 at Oppenheimer 02/25/21 H.C. Wainwright Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright 02/24/21 Stifel Stifel cuts Sage target to $121, reiterates Buy after quarterly results PRAX Praxis Precision Medicines 03/17/21 Piper Sandler Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities 01/21/21 Wedbush Praxis Precision Medicines price target raised to $61 from $51 at Wedbush 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations CERE Cerevel Therapeutics 12/10/20 Goldman Sachs Cerevel Therapeutics initiated with a Buy at Goldman Sachs 11/23/20 Jefferies Cerevel Therapeutics initiated with a Buy at Jefferies 11/09/20 Fly Intel: Top five analyst initiations 11/09/20 Stifel Cerevel Therapeutics initiated with a Buy at Stifel 03/22/21 BofA Karuna Therapeutics initiated with a Buy at BofA 03/01/21 Oppenheimer Karuna Therapeutics price target raised to $148 from $135 at Oppenheimer 02/26/21 Mizuho Karuna Therapeutics price target raised to $150 from $116 at Mizuho 02/26/21 JMP Securities Karuna Therapeutics price target raised to $167 from $122 at JMP Securities 03/08/21 Chardan Passage Bio price target raised to $45 from $35 at Chardan 03/04/21 Citi Citi remains buyer of Passage Bio into first clinical data 03/04/21 Goldman Sachs Passage Bio upgraded to Buy from Neutral at Goldman Sachs 02/04/21 Fly Intel: Top five analyst initiations TSHA Taysha Gene Therapies 03/04/21 Chardan Taysha Gene Therapies price target raised to $60 from $45 at Chardan 02/23/21 William Blair William Blair starts Taysha with Outperform, $46 fair-value estimate 02/23/21 William Blair William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft 02/23/21 William Blair Taysha Gene Therapies initiated with an Outperform at William Blair 03/25/21 Piper Sandler Piper says Biogen Tecfidera patents could change thesis, but sees unknowns 03/25/21 Mizuho Two 'low probability' Biogen events could drive upside, says Mizuho 03/23/21 Piper Sandler Neurologist survey shows erosion for Biogen franchises, says Piper Sandler 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham 03/29/21 Canaccord Stoke Therapeutics weakness a buying opportunity, says Canaccord 03/11/21 Canaccord Stoke Therapeutics price target raised to $76 from $72 at Canaccord 03/10/21 Credit Suisse Stoke Therapeutics price target raised to $58 from $49 at Credit Suisse 02/10/21 Wedbush Stoke Therapeutics downgraded to Neutral at Wedbush 02/03/21 Mizuho Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho 12/04/20 Mizuho Zogenix collaboration step in right direction, says Mizuho 08/24/20 Raymond James Zogenix initiated with a Market Perform at Raymond James 07/15/20 Stifel Physician survey suggests Zogenix shares undervalued, says Stifel AVDL Avadel Pharmaceuticals 03/10/21 H.C. Wainwright Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright 01/25/21 Craig-Hallum Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum 08/28/20 Oppenheimer Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer 08/28/20 SVB Leerink Avadel selloff on Jazz competition worries overdone, says SVB Leerink 03/29/21 H.C. Wainwright uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright 03/02/21 Chardan uniQure price target raised to $100 from $85 at Chardan 12/22/20 Chardan uniQure selloff on clinical hold brings good entry point, says Chardan 12/22/20 Jefferies uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies 02/25/21 Zogenix reports Q4 EPS ($1.26), consensus ($1.00) 11/09/20 Zogenix reports Q3 EPS ($1.08), consensus (98c) XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c) TSHA Taysha Gene Therapies 03/03/21 Taysha Gene Therapies reports Q4 EPS (12c), consensus (37c) 11/13/20 Stoke Therapeutics reports Q3 EPS (41c) vs. (26c) last year 02/24/21 Sage Therapeutics reports Q4 EPS $18.19, consensus (35c) 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) 03/01/21 uniQure reports 2020 EPS ($2.81), consensus ($1.25) 10/27/20 uniQure reports Q3 EPS ($1.21) vs. (58c) last year PRAX Praxis Precision Medicines 03/17/21 Praxis Precision Medicines reports Q4 EPS (87c), two est. (37c) 03/03/21 Passage Bio reports Q4 EPS (85c), consensus (70c) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 02/25/21 Karuna Therapeutics reports Q4 EPS (89c), consensus (89c) 11/05/20 Karuna Therapeutics reports Q3 EPS (71c), consensus (82c) CERE Cerevel Therapeutics 03/24/21 Cerevel Therapeutics reports Q4 EPS (27c), consensus (45c) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open AVDL Avadel Pharmaceuticals 03/09/21 Avadel Pharmaceuticals reports Q4 EPS (19c), consensus (27c) 11/09/20 Avadel Pharmaceuticals reports Q3 EPS (20c), consensus (25c)
Conference/Events
Stifel Virtual CNS Day…
Stifel Virtual CNS Day 2021 will be held on March 31-April 1.
Show Hide Related Items >> <<
01/11/21 Zogenix announces 2021 corporate objectives 01/11/21 Zogenix sees Q4 FINTEPLA revenue $8.1M 12/21/20 Zogenix announces EC approval of FINTEPLA oral solution 12/03/20 Zogenix and Tevard Biosciences to develop therapies for Dravet syndrome XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO TSHA Taysha Gene Therapies 03/09/21 Taysha Gene Therapies announces collaboration to advance AAV gene therapies 02/09/21 Taysha Gene Therapies announces multi-year collaborations for AAV gene therapies 01/26/21 Taysha Gene Therapies appoints Timothy Douros as CLO, Tracy Porter as CPO 01/19/21 Taysha gets both rare pediatric disease and orphan drug designations for TSHA-10 03/30/21 Stoke Therapeutics gets MHRA authorization to start clinical trial of STK-001 11/25/20 Stoke Therapeutics announces abstracts for Dravet syndrome at AES 2020 10/07/20 Stoke Therapeutics to move forward with dosing of STK-001 in MONARCH study 03/17/21 Sage Therapeutics' zuranolone for depression shows positive Phase 3 results 03/16/21 Sage Therapeutics announces departure of COO Mike Cloonan 01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 03/29/21 uniQure announces findings from case of HCC in Hemophilia B gene therapy program 03/01/21 uniQure expects cash to fund operations into 2H22 02/08/21 uniQure says DSMB recommends proceeding with Phase I/II trial of AMT-130 12/21/20 uniQure says hemophilia B gene therapy program placed on clinical hold PRAX Praxis Precision Medicines 03/17/21 Praxis Precision Medicines expects cash to fund operations into 4Q22 02/16/21 Praxis Precision Medicines partners with Ciitizen 01/07/21 Praxis receives rare pediatric disease, orphan drug designations for PRAX-222 12/01/20 Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor 03/22/21 Passage Bio appoints Eliseo Salinas as chief R&D officer 03/08/21 Passage Bio to start PBFT02 clinical program in 1H21 03/08/21 Passage Bio to start Phase 1/2 trial of PBKR03 in 1H21 03/08/21 Passage Bio to dose first patient in global Imagine-1 study in Q1 02/25/21 Karuna announces data from KarXT study in Schizophrenia published 02/25/21 Karuna Therapeutics sees cash, cash equivalents, sufficient into 2023 02/24/21 Karuna Therapeutics' KarXT in schizophrenia meets Phase 2 efficacy endpoint 10/14/20 Karuna says no incidences of syncope reported in KarXT trial CERE Cerevel Therapeutics 01/28/21 Cerevel Therapeutics hosts R&D event to review darigabat 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/19/21 Inspire appoints Bryan Phillips as chief compliance officer, general counsel 01/19/21 Frequency Therapeutics appoints Quentin McCubbin as chief manufacturing officer 03/25/21 Biogen up 3% after tweet claims Tecfidera patents to be granted 03/21/21 Fly Intel: Top five weekend stock stories 03/04/21 Biogen to build gene therapy manufacturing center in North Carolina 03/04/21 Dyne Therapeutics appoints Wildon Farwell as CMO AVDL Avadel Pharmaceuticals 03/04/21 Avadel, AASM Foundation partner with Young Investigators Research Forum 03/02/21 Avadel Pharmaceuticals announces publication on FT218 studies 03/01/21 Avadel Pharmaceuticals announces FDA acceptance of FT218 NDA 02/17/21 Avadel Pharmaceuticals appoints Richard Kim as CCO 02/26/21 Mizuho Sage Therapeutics downgraded to Neutral from Buy at Mizuho 02/25/21 Oppenheimer Sage Therapeutics price target raised to $102 from $90 at Oppenheimer 02/25/21 H.C. Wainwright Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright 02/24/21 Stifel Stifel cuts Sage target to $121, reiterates Buy after quarterly results PRAX Praxis Precision Medicines 03/17/21 Piper Sandler Piper sees 114 IND, pivotal trial as sign of Praxis regulatory capabilities 01/21/21 Wedbush Praxis Precision Medicines price target raised to $61 from $51 at Wedbush 11/17/20 Piper Sandler Praxis Precision clinical hold looks like 'formality,' says Piper Sandler 11/11/20 Fly Intel: Top five analyst initiations CERE Cerevel Therapeutics 12/10/20 Goldman Sachs Cerevel Therapeutics initiated with a Buy at Goldman Sachs 11/23/20 Jefferies Cerevel Therapeutics initiated with a Buy at Jefferies 11/09/20 Fly Intel: Top five analyst initiations 11/09/20 Stifel Cerevel Therapeutics initiated with a Buy at Stifel 03/22/21 BofA Karuna Therapeutics initiated with a Buy at BofA 03/01/21 Oppenheimer Karuna Therapeutics price target raised to $148 from $135 at Oppenheimer 02/26/21 Mizuho Karuna Therapeutics price target raised to $150 from $116 at Mizuho 02/26/21 JMP Securities Karuna Therapeutics price target raised to $167 from $122 at JMP Securities 03/08/21 Chardan Passage Bio price target raised to $45 from $35 at Chardan 03/04/21 Citi Citi remains buyer of Passage Bio into first clinical data 03/04/21 Goldman Sachs Passage Bio upgraded to Buy from Neutral at Goldman Sachs 02/04/21 Fly Intel: Top five analyst initiations TSHA Taysha Gene Therapies 03/04/21 Chardan Taysha Gene Therapies price target raised to $60 from $45 at Chardan 02/23/21 William Blair William Blair starts Taysha with Outperform, $46 fair-value estimate 02/23/21 William Blair William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft 02/23/21 William Blair Taysha Gene Therapies initiated with an Outperform at William Blair 03/25/21 Piper Sandler Piper says Biogen Tecfidera patents could change thesis, but sees unknowns 03/25/21 Mizuho Two 'low probability' Biogen events could drive upside, says Mizuho 03/23/21 Piper Sandler Neurologist survey shows erosion for Biogen franchises, says Piper Sandler 02/17/21 Cantor Fitzgerald Biogen price target lowered to $268 from $278 at Cantor Fitzgerald XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham 03/29/21 Canaccord Stoke Therapeutics weakness a buying opportunity, says Canaccord 03/11/21 Canaccord Stoke Therapeutics price target raised to $76 from $72 at Canaccord 03/10/21 Credit Suisse Stoke Therapeutics price target raised to $58 from $49 at Credit Suisse 02/10/21 Wedbush Stoke Therapeutics downgraded to Neutral at Wedbush 02/03/21 Mizuho Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho 12/04/20 Mizuho Zogenix collaboration step in right direction, says Mizuho 08/24/20 Raymond James Zogenix initiated with a Market Perform at Raymond James 07/15/20 Stifel Physician survey suggests Zogenix shares undervalued, says Stifel AVDL Avadel Pharmaceuticals 03/10/21 H.C. Wainwright Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright 01/25/21 Craig-Hallum Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum 08/28/20 Oppenheimer Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer 08/28/20 SVB Leerink Avadel selloff on Jazz competition worries overdone, says SVB Leerink 03/29/21 H.C. Wainwright uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright 03/02/21 Chardan uniQure price target raised to $100 from $85 at Chardan 12/22/20 Chardan uniQure selloff on clinical hold brings good entry point, says Chardan 12/22/20 Jefferies uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies 02/25/21 Zogenix reports Q4 EPS ($1.26), consensus ($1.00) 11/09/20 Zogenix reports Q3 EPS ($1.08), consensus (98c) XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c) TSHA Taysha Gene Therapies 03/03/21 Taysha Gene Therapies reports Q4 EPS (12c), consensus (37c) 11/13/20 Stoke Therapeutics reports Q3 EPS (41c) vs. (26c) last year 02/24/21 Sage Therapeutics reports Q4 EPS $18.19, consensus (35c) 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) 03/01/21 uniQure reports 2020 EPS ($2.81), consensus ($1.25) 10/27/20 uniQure reports Q3 EPS ($1.21) vs. (58c) last year PRAX Praxis Precision Medicines 03/17/21 Praxis Precision Medicines reports Q4 EPS (87c), two est. (37c) 03/03/21 Passage Bio reports Q4 EPS (85c), consensus (70c) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 02/25/21 Karuna Therapeutics reports Q4 EPS (89c), consensus (89c) 11/05/20 Karuna Therapeutics reports Q3 EPS (71c), consensus (82c) CERE Cerevel Therapeutics 03/24/21 Cerevel Therapeutics reports Q4 EPS (27c), consensus (45c) 02/03/21 Biogen sees FY21 adjusted EPS $17.00-$18.50, consensus $24.67 02/03/21 Biogen reports Q4 adjusted EPS $4.58, consensus $4.87 02/02/21 Notable companies reporting before tomorrow's open AVDL Avadel Pharmaceuticals 03/09/21 Avadel Pharmaceuticals reports Q4 EPS (19c), consensus (27c) 11/09/20 Avadel Pharmaceuticals reports Q3 EPS (20c), consensus (25c)
Conference/Events
Healthcare Analysts Tsai…
Healthcare Analysts Tsai & Windley, along with Drs. Sullivan & Rao provide an expert update on Epilepsy on an Analyst/Industry conference call to be held on March 31 at 10 am.
Show Hide Related Items >> <<
01/11/21 Zogenix announces 2021 corporate objectives 01/11/21 Zogenix sees Q4 FINTEPLA revenue $8.1M 12/21/20 Zogenix announces EC approval of FINTEPLA oral solution 12/03/20 Zogenix and Tevard Biosciences to develop therapies for Dravet syndrome XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO MRNS Marinus Pharmaceuticals 03/09/21 Marinus Pharmaceuticals CFO Edward Smith to leave, Steven Pfanstiel to succeed 01/26/21 Marinus Pharmaceuticals enrolls first patent in IV ganaxolone trial 01/13/21 Marinus gets response from FDA on sufficiency of one trial for NDA filing 01/13/21 Marinus gets response from FDA on sufficiency of one trial for NDA filing JAZZ Jazz Pharmaceuticals 03/30/21 Jazz announces FDA approved revised label for Vyxeos 02/16/21 Jazz completes rolling submission for sNDA to FDA for Xywav oral solution 02/03/21 Jazz, GW Pharmaceuticals combo expected to accretive in first full year 02/03/21 Jazz Pharmaceuticals to acquire GW Pharmaceuticals for $220.00 per ADS 02/26/21 GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX 02/03/21 GW Pharmaceuticals trading resumes 03/29/21 GlaxoSmithKline to support manufacture of Novavax' COVID-19 vaccine 03/29/21 GlaxoSmithKline to support manufacture of Novavax' COVID-19 vaccine in UK 03/29/21 Eli Lilly, Vir, GSK announces topline data from Phase 2 BLAZE-4 trial 03/29/21 Eli Lilly, Vir Biotechnology, GlaxoSmithKline: Positive data from Phase 2 BLAZE JAZZ Jazz Pharmaceuticals 03/01/21 UBS Jazz Pharmaceuticals price target raised to $228 from $174 at UBS 02/24/21 Cowen Jazz Pharmaceuticals price target raised to $200 from $190 at Cowen 02/24/21 Jefferies Jazz Pharmaceuticals price target raised to $214 from $209 at Jefferies 02/24/21 Piper Sandler Jazz Pharmaceuticals price target raised to $205 from $175 at Piper Sandler 02/05/21 H.C. Wainwright Jazz Pharmaceuticals price target raised to $207 from $195 at H.C. Wainwright 02/04/21 SVB Leerink GW Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink 02/04/21 GW Pharmaceuticals downgraded to Neutral from Buy at Citi 02/04/21 H.C. Wainwright GW Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright 03/23/21 Fly Intel: Top five analyst downgrades 03/23/21 SVB Leerink SVB Leerink moving to sidelines on Alexion, five others on industry concerns 03/23/21 SVB Leerink GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink 03/08/21 JPMorgan JPMorgan double downgrades AnaptysBio back to Underweight after trial miss 02/03/21 Mizuho Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho 12/04/20 Mizuho Zogenix collaboration step in right direction, says Mizuho 08/24/20 Raymond James Zogenix initiated with a Market Perform at Raymond James 07/15/20 Stifel Physician survey suggests Zogenix shares undervalued, says Stifel XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham MRNS Marinus Pharmaceuticals 03/10/21 H.C. Wainwright Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright 11/10/20 Cantor Fitzgerald Marinus Pharmaceuticals price target raised to $27 from $8 at Cantor Fitzgerald 09/30/20 Truist Marinus Pharmaceuticals initiated with a Buy at Truist 09/25/20 JMP Securities Marinus Pharmaceuticals price target raised to $26 from $7 at JMP Securities 02/25/21 Zogenix reports Q4 EPS ($1.26), consensus ($1.00) 11/09/20 Zogenix reports Q3 EPS ($1.08), consensus (98c) XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c) MRNS Marinus Pharmaceuticals 03/09/21 Marinus Pharmaceuticals reports Q4 EPS (55c), consensus (51c) 11/09/20 Marinus Pharmaceuticals reports Q3 EPS (51c), consensus (60c) JAZZ Jazz Pharmaceuticals 02/23/21 Jazz Pharmaceuticals sees FY21 adjusted EPS $15.65-$16.85, consensus $16.78 02/23/21 Jazz Pharmaceuticals reports Q4 EPS $4.00, consensus $4.20 02/16/21 GW Pharmaceuticals reports Q4 EPS (8c), consensus (60c) 11/02/20 Jazz Pharma narrows FY20 non-GAAP EPS view to $12.20-$13.00 from $11.90-$13.00 01/11/21 GW Pharmaceuticals sees 2020 revenue $526M, consensus $519.52M 01/11/21 GW Pharmaceuticals sees Q4 revenue $148M, consensus $140.44M 11/03/20 GW Pharmaceuticals reports Q3 EPS (3c), consensus (83c) 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
Over a quarter ago
On The Fly
Check out this morning's…
Show Hide Related Items >> <<
02/01/21 Robinhood raises $3.4B to continue investing in customer growth 01/29/21 Robinhood updates limit on GameStop buys to one share, restricts other positions XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO UNFI United Natural Foods 03/04/21 United Natural Foods rises 15.1% 03/04/21 United Natural Foods extends distribution pact with Whole Foods Market 12/09/20 United Natural Foods falls -15.3% 12/09/20 United Natural Foods falls -12.2% 03/10/21 Tupperware Brands drops 10% to $29.29 after Q4 earnings miss 03/10/21 Tupperware Brands CEO: Efforts to fix the core business beginning to take hold 01/12/21 Tupperware Brands falls -7.7% 12/03/20 Tupperware moves up after note refinancing, going concern issue 'solved' 02/11/21 Tempur Sealy rises 15.1% 02/11/21 Tempur Sealy raises authorization of share repurchase program to $400M 02/11/21 Tempur Sealy initiates cash dividend in Q1 with 7c per share 11/16/20 Einhorn's Greenlight buys Twitter, exits Whirlpool in Q3 10/29/20 Ontrak acquires behavior change platform LifeDojo 10/13/20 Ontrak rises after announcing launch of Ontrak-CI program 03/09/21 MediciNova partners with BARDA to develop MN-166 as lung injury countermeasure 03/03/21 MediciNova to discontinue development of SARS-CoV-2 vaccine for COVID-19 01/21/21 MediciNova rises 14% after disclosing activist stake by 3D Investment Partners 12/29/20 MediciNova receives notice of allowance for patent covering MN-166 03/10/21 General Electric has 'significant' sources of funds to lower debt, CFO says 03/10/21 General Electric sees 2021 free cash flow margin of 3.5%-6% 03/10/21 General Electric to reach high single digit free cash flow margins by 2023 03/10/21 General Electric to lower receivables factoring to $2B from $7B 03/10/21 Campbell Soup says 'well-positioned to generate significant cash flow' 03/10/21 Campbell Soup says Q3 to be 'somewhat more challenged' than Q4 03/10/21 Campbell Soup expects $75M-$85M in cost savings in FY21 03/10/21 Campbell Soup says 'thrilled' with performance of Pacific Foods 12/31/20 Build-A-Bear falls -5.9% 12/17/20 Build-A-Bear announces partnership with Shipt for same-day delivery 11/17/20 Build-A-Bear falls -10.7% 03/10/21 Affimed N.V. to continue enrollment in AFM13 study after positive interim data 02/08/21 Point72 Asset Management reports 5.0% passive stake in Affimed N.V. 02/03/21 Affimed N.V. announces pact with Roche to study AFM24/atezolizumab combo 01/07/21 Affimed N.V. provides pipeline and business update 03/10/21 GE CEO: Had 'dialogue ongoing for some time' with AerCap CEO 03/10/21 GE CEO: AerCap an 'excellent partner' for GECAS 03/10/21 General Electric sees Q1 $3B non-cash charge in connection with GECAS deal 03/10/21 GE to get 111.5M newly issued AerCap shares, $24B cash 03/09/21 Citi General Electric deal with AerCap would be viewed positively, says Citi 03/08/21 Stephens Stephens positive on AerCap reportedly buying GECAS 01/26/21 Cowen AerCap price target raised to $54 from $50 at Cowen 12/21/20 Deutsche Bank AerCap price target raised to $55 from $44 at Deutsche Bank 03/10/21 Maxim MediciNova initiated with a Buy at Maxim 03/10/21 Maxim MediciNova initiated with a Buy at Maxim UNFI United Natural Foods 02/19/21 Fly Intel: Top five analyst initiations 02/19/21 Seaport Global United Natural Foods initiated with a Neutral at Seaport Global 01/28/21 MKM Partners United Natural Foods price target raised to $36 from $26 at MKM Partners 01/28/21 Northcoast United Natural Foods downgraded to Neutral from Buy at Northcoast 03/02/21 B. Riley Ontrak price target lowered to $73 from $110 at B. Riley Securities 03/02/21 Cowen Cowen downgrades Ontrak to Market Perform until visibility returns 03/02/21 Canaccord Canaccord downgrades Ontrak after loss of largest customer 03/02/21 Cowen Ontrak downgraded to Market Perform from Outperform at Cowen 02/25/21 Deutsche Bank Campbell Soup price target lowered to $50 from $52 at Deutsche Bank 01/12/21 Jefferies Campbell Soup price target lowered to $54 from $58 at Jefferies 12/10/20 Credit Suisse Campbell Soup price target lowered to $49 from $55 at Credit Suisse 10/19/20 Citi Campbell Soup initiated with a Neutral at Citi 09/25/20 Citi Tupperware Brands price target raised to $28 from $15 at Citi 09/24/20 DA Davidson Tupperware can stabilize core business, grow organic sales, says DA Davidson 09/15/20 Fly Intel: Top five analyst initiations 09/15/20 DA Davidson Tupperware Brands initiated with a Buy at DA Davidson 03/10/21 BMO Capital Qualtrics price target lowered to $45 from $52 at BMO Capital 03/10/21 Oppenheimer Qualtrics price target lowered to $55 from $60 at Oppenheimer 03/10/21 Citi Qualtrics price target lowered to $55 from $61 at Citi 03/10/21 Oppenheimer Qualtrics should be bought on pullbacks after 'strong' Q4, says Oppenheimer 03/04/21 Morgan Stanley General Electric price target raised to $17 from $13 at Morgan Stanley 03/02/21 Barclays Danaher started at Overweight at Barclays on GE biopharma business potential 03/10/21 Loop Capital Tempur Sealy downgraded to Hold from Buy at Loop Capital 02/18/21 UBS Tempur Sealy upgraded to Buy from Neutral at UBS 02/12/21 Truist Tempur Sealy price target raised to $45 from $31 at Truist 01/26/21 Loop Capital Tempur Sealy price target raised to $35 from $30 at Loop Capital XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham 03/09/21 Notable companies reporting after market close XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c) UNFI United Natural Foods 03/10/21 United Natural Foods backs FY21 adjusted EPS view $3.05-$3.55, consensus $3.17 03/10/21 United Natural Foods reports Q2 adjusted EPS $1.25, consensus 81c 03/09/21 Notable companies reporting before tomorrow's open 03/10/21 Tupperware Brands reports Q4 adjusted EPS 14c, consensus 71c 10/28/20 Tupperware Brands reports Q3 adjusted EPS $1.20, consensus 37c 02/11/21 Tempur Sealy sees FY21 EPS $2.30-$2.50, consensus $1.99 02/11/21 Tempur Sealy reports Q4 adjusted EPS 67c, consensus 52c 12/09/20 Tempur Sealy sees Q4 revenue up low double digits, consensus $987.5M 10/29/20 Tempur Sealy reports Q3 adj. EPS $2.94, consensus $2.20 03/09/21 Ontrak sees FY21 revenue $100M, consensus $97.07M 03/09/21 Ontrak reports Q4 adjusted EPS (7c), consensus (39c) 03/01/21 Ontrak sees FY21 revenue $100M, consensus $165.05M 03/01/21 Ontrak reports Q4 EPS (7c), consensus (30c) 03/10/21 General Electric sees FY21 adjusted EPS 15c-25c, consensus 26c 01/26/21 General Electric sees FY21 adjusted EPS 15c-25c, consensus 38c 01/26/21 General Electric reports Q4 adjusted EPS 8c, consensus 9c 01/25/21 Notable companies reporting before tomorrow's open 03/10/21 Campbell Soup sees FY21 adjusted EPS $3.03-$3.11, consensus $3.03 03/10/21 Campbell Soup reports Q2 adjusted EPS 84c, consensus 84c 03/10/21 Build-A-Bear sees FY21 EBITDA higher than FY19 EBITDA of $15.3M 03/10/21 Build-A-Bear reports Q4 adjusted EPS 47c, one estimate 16c 01/11/21 Build-A-Bear sees Q4 revenue $88M-$92M, one estimate $100.56M 12/03/20 Build-A-Bear reports Q3 EPS 11c, one estimate (4c) 03/02/21 AerCap reports Q4 EPS 22c, consensus 94c 11/10/20 AerCap reports Q3 adjusted EPS $1.24, consensus $1.43
Syndicate
The deal size was…
The deal size was increased to $100M from $60M and priced below the last closing price of $20.04. Jefferies, Stifel and William Blair are acting as joint book running managers for the offering.
Show Hide Related Items >> <<
XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c)
On The Fly
Check out this evening's…
Show Hide Related Items >> <<
XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO 03/09/21 Sonos targets FY24 revenue $2.25B 12/15/20 Sonos and Legrand sign multi-year licensing deal, terms undisclosed 11/18/20 Sonos jumps 20.5% to $20.60 after Q4 earnings beat 11/18/20 Sonos board authorizes up to $50M share repurchase program 10/29/20 Ontrak acquires behavior change platform LifeDojo 10/13/20 Ontrak rises after announcing launch of Ontrak-CI program 02/23/21 Oak Street Health to enter Georgia, extending national footprint to 14 states 12/16/20 Oak Street Health opens community clinics at three Walmart locations in Texas 12/09/20 Oak Street Health's Clem sells 100,000 common shares 12/08/20 Oak Street Health to enter Louisiana, South Carolina in early 2021 11/19/20 Outset Medical deploys 15 Tablo Hemodialysis Systems to hospitals in Guam 11/09/20 Outset Medical appoints Steve Williamson as Chief Commercial Officer 01/25/21 Inari Medical to present chronic clot subanalysis results 01/08/21 Inari Medical's FlowTriever system receives 510(k) clearance 11/13/20 Inari Medical presents 30-day follow-up results from FLASH study 10/19/20 Inari Medical announces presentation of results from real world FLASH registry 03/09/21 MediciNova partners with BARDA to develop MN-166 as lung injury countermeasure 03/03/21 MediciNova to discontinue development of SARS-CoV-2 vaccine for COVID-19 01/21/21 MediciNova rises 14% after disclosing activist stake by 3D Investment Partners 12/29/20 MediciNova receives notice of allowance for patent covering MN-166 $310.95 / +23.59 (+8.21%)
02/25/21 MongoDB expands integration of Atlas database with Google Cloud 02/16/21 Lone Pine bought Snap and Carvana during Q4, exited PayPal 12/08/20 MongoDB reports over 22,600 customers as of October 31 12/08/20 MongoDB reports Q3 subscription revenue $144.1M, up 39% y/y 01/12/21 Open Lending signs Royal Credit Union to Lenders Protection Program 12/16/20 Open Lending signs Members 1st Federal Credit Union to lenders protection 09/14/20 Open Lending signs Sound Credit Union to Lenders Protection Program 02/25/21 Jounce Therapeutics sees cash, cash equivalents sufficient into 2Q23 02/12/21 Jounce Therapeutics appoints Luisa Salter-Cid to board of directors 01/29/21 Adage Capital reports 6.95% passive stake in Jounce Therapeutics 01/13/21 Jounce Therapeutics initiates patient enrollment in Phase 1 INNATE study 12/08/20 H&R Block to present next phase of strategic transformation 10/19/20 Truist Financial names Vinoo Vijay as Chief Marketing Officer 10/06/20 H&R Block appoints Yolande Piazza to board of directors 03/09/21 Everi Holdings sees Q1 operating and financial results to exceed Q120 01/22/21 Everi launches online games in Michigan 03/04/21 Clean Energy, Total sign Joint Venture to develop carbon-negative fuel 02/08/21 Clean Energy signs new agreement with LA metro 12/21/20 Clean Energy, BP intend to create renewable natural gas joint venture 12/21/20 Clean Energy, Total announce MOU to create 50/50 RNG joint venture 03/09/21 Avid Technology sees FY21 free cash flow $45M-$52M 03/08/21 Avid Technology launches Avid Edit On Demand subscription service 02/23/21 Avid Technology names Adistec as master distributor in Latin America 02/04/21 Avid reports downloads of over 3M copies of 'first' versions of creative tools APEI American Public Education 01/15/21 California AG sues Education Department over for-profit collegerule easing 10/29/20 American Public Education to acquire Rasmussen for $329M in cash, stock 02/11/21 ABM partners with ASM Global to execute VenueShield program 01/26/21 ABM initiates fifth phase ESPC for Madison County Schools 12/16/20 ABM announces 2.7% boost to quarterly cash dividend to 19c per share 11/12/20 ABM initiates ESPC for GSA, projected to save $34.3M in energy reduction 12/15/20 Oppenheimer Oppenheimer starts Outset Medical at Perform, citing competition 12/15/20 Oppenheimer Outset Medical initiated with a Perform at Oppenheimer 10/12/20 Fly Intel: Top five analyst initiations 10/12/20 Morgan Stanley Outset Medical initiated with an Equal Weight at Morgan Stanley 01/21/21 BTIG Inari Medical price target raised to $110 from $92 at BTIG 01/20/21 Wells Fargo Inari Medical price target raised to $112 from $79 at Wells Fargo 12/15/20 Wells Fargo Wells Fargo says Buy Inari Medical, Sell NuVasive in MedTech ratings shake-up 12/15/20 Wells Fargo Inari Medical upgraded to Overweight from Equal Weight at Wells Fargo 03/02/21 B. Riley Ontrak price target lowered to $73 from $110 at B. Riley Securities 03/02/21 Cowen Cowen downgrades Ontrak to Market Perform until visibility returns 03/02/21 Canaccord Canaccord downgrades Ontrak after loss of largest customer 03/02/21 Cowen Ontrak downgraded to Market Perform from Outperform at Cowen 01/06/21 CL King ABM named best idea for 2021 amid 'misperception' at CL King 12/21/20 CL King ABM price target raised to $48 from $45 at CL King 12/14/20 CL King Adoption of ABM's EnhancedClean driving higher-margin growth, says CL King 09/17/20 Sidoti ABM upgraded to Buy from Neutral at Sidoti 03/04/21 William Blair Open Lending initiated with an Outperform at William Blair 02/10/21 Needham Open Lending initiated with a Buy at Needham 01/20/21 DA Davidson Open Lending price target raised to $45 from $31 at DA Davidson 01/04/21 Deutsche Bank Open Lending named 'Catalyst Call: Buy Idea' at Deutsche Bank 02/18/21 BTIG Everi Holdings price target raised to $21 from $16 at BTIG 01/26/21 Craig-Hallum Everi Holdings price target raised to $20 from $13 at Craig-Hallum 01/19/21 Jefferies Everi Holdings price target raised to $16 from $14 at Jefferies 12/09/20 Stifel Everi Holdings resumed with a Buy at Stifel APEI American Public Education 12/18/20 B. Riley B. Riley starts 'compelling' American Public Education with Buy rating 12/18/20 B. Riley American Public Education initiated with a Buy at B. Riley Securities 11/10/20 Barrington American Public Education price target raised to $40 from $37 at Barrington 11/02/20 Sidoti American Public Education upgraded to Buy from Neutral at Sidoti $310.95 / +23.59 (+8.21%)
03/08/21 Morgan Stanley Software industry rating raised to Attractive from In-Line at Morgan Stanley 02/23/21 Citi MongoDB price target raised to $500 from $465 at Citi 01/19/21 Needham MongoDB price target raised to $394 from $341 at Needham 01/15/21 Stifel Elastic upgraded to Buy after licensing changes at Stifel 02/11/21 Lake Street Clean Energy price target raised to $27 from $9 at Lake Street 02/08/21 Craig-Hallum Clean Energy price target raised to $25 from $12 at Craig-Hallum 02/03/21 Fly Intel: Top five analyst initiations 02/03/21 Credit Suisse Clean Energy initiated with an Outperform at Credit Suisse 03/03/21 B. Riley Avid Technology price target raised to $24 from $18 at B. Riley Securities 02/09/21 Northland Avid Technology price target raised to $32 from $22 at Northland 12/31/20 B. Riley Avid Technology price target raised to $18 from $13.50 at B. Riley Securities 10/29/20 B. Riley Avid Technology price target raised to $13.50 from $12 at B. Riley Securities 02/24/21 Canaccord Canaccord starts Oak Street Health at Buy with $67 price target 02/24/21 Canaccord Oak Street Health initiated with a Buy at Canaccord 02/17/21 Piper Sandler Oak Street Health price target raised to $69 from $59 at Piper Sandler 01/28/21 Wolfe Research Oak Street Health initiated with an Outperform at Wolfe Research 10/30/20 BTIG BTIG thinks those looking to potentially short Square, H&R Block should wait 09/03/20 BMO Capital H&R Block price target lowered to $17 from $19 at BMO Capital 09/01/20 BTIG H&R Block's tax season distorted by pandemic, say BTIG 07/15/20 Northcoast H&R Block upgraded to Buy from Neutral at Northcoast 02/26/21 H.C. Wainwright Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright 12/04/20 H.C. Wainwright Jounce Therapeutics assumed with a Buy at H.C. Wainwright 11/10/20 Roth Capital Jounce Therapeutics price target lowered to $15 from $28 at Roth Capital 11/03/20 Raymond James Jounce downgraded to Market Perform from Strong Buy at Raymond James XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham 03/05/21 Morgan Stanley Sonos analyst day to be positive catalyst for shares, says Morgan Stanley 02/11/21 Goldman Sachs Sonos upgraded to Neutral from Sell at Goldman Sachs 02/11/21 Morgan Stanley Sonos price target raised to $45 from $35 at Morgan Stanley 02/03/21 Morgan Stanley Morgan Stanley raises price target on 'top small cap' pick Sonos to $35 XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c) 02/10/21 Sonos raises FY21 revenue view to $1.525B-$1.575B from $1.44B-$1.5B 02/10/21 Sonos reports Q1 adjusted EPS $1.17, consensus 88c 11/18/20 Sonos sees FY21 revenue $1.44B-$1.5B, consensus $1.38B 11/18/20 Sonos reports Q4 adjusted EPS 33c, consensus 0c 03/09/21 Ontrak sees FY21 revenue $100M, consensus $97.07M 03/09/21 Ontrak reports Q4 adjusted EPS (7c), consensus (39c) 03/01/21 Ontrak sees FY21 revenue $100M, consensus $165.05M 03/01/21 Ontrak reports Q4 EPS (7c), consensus (30c) 03/09/21 Oak Street Health sees FY21 revenue $1.275B-$1.325B, consensus $1.29B 03/09/21 Oak Street Health sees Q1 revenue $280M-$285M, consensus $276.25M 03/09/21 Oak Street Health reports Q4 EPS (40c), consensus (26c) 03/09/21 Outset Medical sees Q1 revenue $21M-$22M, consensus $14.79M 03/09/21 Outset Medical sees FY21 revenue $89M-$94M, consensus $$71.26M 03/09/21 Outset Medical reports Q4 EPS (60c), consensus (66c) 11/11/20 Outset Medical reports Q3 EPS ($2.31), consensus ($3.10) 03/09/21 Inari Medical reports Q4 EPS 13c, consensus 1c 01/13/21 Inari Medical sees Q4 revenue $47.9M-$48.9M, consensus $38.5M 11/12/20 Inari Medical reports Q3 EPS 12c, consensus (4c) $310.95 / +23.59 (+8.21%)
03/09/21 MongoDB sees FY22 adjusted EPS ($1.55)-($1.39), consensus (98c) 03/09/21 MongoDB sees Q1 adjusted EPS (39c)-(36c), consensus (27c) 03/09/21 MongoDB reports Q4 adjusted EPS (33c), consensus (39c) 03/09/21 Open Lending backs FY21 revenue view $184M-$234M, consensus $216.36M 03/09/21 Open Lending reports Q4 EPS 12c, consensus 12c 03/09/21 Notable companies reporting after market close 02/25/21 Jounce Therapeutics reports Q4 EPS 86c, consensus 22c 11/06/20 Jounce Therapeutics reports Q3 EPS (73c), consensus (47c) 03/09/21 H&R Block reports Q3 adjusted EPS ($1.17), consensus ($1.29) 12/08/20 H&R Block reports Q2 adj. EPS ($1.09), consensus (94c) 12/07/20 Notable companies reporting before tomorrow's open 03/09/21 Everi Holdings reports Q4 EPS 1c, consensus 0c 01/26/21 Everi Holdings sees Q4 revenue $117M-$121M, consensus $114.27M 11/02/20 Everi Holdings reports Q3 EPS (1c), consensus (19c) 03/09/21 Clean Energy reports Q4 adjusted EPS 0c, consensus 0c 11/05/20 Clean Energy reports Q3 EPS (1c), consensus (2c) 03/09/21 Avid Technology sees Q1 EPS 17c-24c, consensus 20c 03/09/21 Avid Technology reports Q4 EPS 16c, consensus 32c 10/28/20 Avid Technology reports Q3 EPS 27c, consensus 13c APEI American Public Education 03/09/21 American Public Education sees Q1 EPS 39c-44c, consensus 22c 03/09/21 American Public Education reports Q4 EPS 47c, consensus 41c 11/09/20 American Public Education sees Q4 EOS 41c-46c, consensus 45c 11/09/20 American Public Education reports Q3 EPS 18c, consensus 15c 03/09/21 ABM sees FY21 EPS $3.00-$3.25, consensus $2.41 03/09/21 ABM reports Q1 EPS $1.01, consensus 59c 12/16/20 ABM sees Q1 EPS 60c-65c, consensus 47c 12/16/20 ABM reports Q4 EPS 69c, consensus 70c
Syndicate
Jefferies, Stifel and…
Jefferies, Stifel and William Blair are acting as joint book running managers for the offering.
Show Hide Related Items >> <<
XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c)
Syndicate
Jefferies, Stifel, and…
Jefferies, Stifel, and William Blair are acting as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow are acting as co-managers for the offering.
Show Hide Related Items >> <<
XENE Xenon Pharmaceuticals 02/22/21 Xenon Pharmaceuticals annponces data from XEN1101 program at ASENT 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for partnered programs 01/14/21 Xenon Pharmaceuticals announces anticipated milestones for proprietary programs 01/14/21 Xenon appoints Simon Pimstone as executive chair, Ian Mortimer as CEO XENE Xenon Pharmaceuticals 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 10/02/20 SVB Leerink Xenon Pharmaceuticals initiated with an Outperform at SVB Leerink 07/21/20 Fly Intel: Top five analyst initiations 07/21/20 Needham Xenon Pharmaceuticals initiated with a Buy at Needham XENE Xenon Pharmaceuticals 11/05/20 Xenon Pharmaceuticals reports Q3 EPS (25c), consensus (15c)